Apollo Pharmaceuticals Products Available to Intalere Members through New Intalere Choice Agreement
St. Louis (June 1, 2020) – Intalere Choice, the preferred portfolio subsidiary of Intalere, the healthcare industry leader in delivering solutions designed for improved financial, operational and clinical health for our partners, announces a new pharmaceutical agreement with Apollo Pharmaceuticals USA, Inc.
Through this agreement Intalere members will receive negotiated pricing on generic injectables. Apollo Pharmaceuticals provides innovative product formulations and preferred container closure systems for the primary benefit of the patient and to ease the administration of the product for the end user.
This contract is currently effective through July 31, 2024.
About Apollo Pharmaceuticals USA, Inc.
Apollo Pharmaceuticals is an entrepreneurial family owned pharmaceutical company with proven expertise in the development, manufacturing and distribution of sterile injectable products. Capitalizing on our in-house R&D Lab and FDA approved QC Lab, pilot manufacturing suite and an established network of global manufacturing partners, we ensure consistent and reliable supply of customer driven products to the US market. Learn more at www.apollopharmainc.com.
Intalere’s mission focuses on elevating the health of healthcare by designing solutions to improve our members’ financial, operational and clinical performance. We empower our customers and deliver measurable results through our highly personalized approach of creating strategies and programs focused on their goals. From managing their entire spend to strategic consulting around diagnosing particular areas of concern, our unique provider led model allows us to leverage nationally recognized best practices in supply chain and patient outcomes to drive efficiencies for our members. To learn more, visit www.intalere.com.